DGAP-News: SphingoTec GmbH / Key word(s): Corporate Action/Strategic Company Decision SphingoTec Expands Management Team and Appoints new CFO 10.06.2021 / 10:00 The issuer is solely responsible for the content of this announcement. Dr. Angelo Moesslang was named CFO and Managing Director of Sphi.
DGAP-News: SphingoTec Accelerates Growth with Direct Sales
vom 20.05.2021, 10:00 Uhr
Bild: pixabay.com
SphingoTec Accelerates Growth with Direct Sales
20.05.2021 / 10:00
The issuer is solely responsible for the content of this announcement.
SphingoTec to expand the commercialization strategy by establishing a sales division and appointing new head of sales
Tailored diagnostic solutions for point of care use
Innovative proprietary biomarkers and standard parameters available on the fully automated Nexus IB10 platform
Hennigsdorf/Berlin, Germany, May 20, 2021 - Diagnostics company SphingoTec GmbH ( SphingoTec ) announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic solutions. SphingoTec will sell directly to healthcare providers its Nexus IB10 point of care platform together with a broad portfolio of assays. The rapid tests include commonly used parameters as well as innovative and pro
DGAP-News: SphingoTec GmbH / Key word(s): Corporate Action/Strategic Company Decision SphingoTec Accelerates Growth with Direct Sales 20.05.2021 / 10:00 The issuer is solely responsible
Investegate announcements from SphingoTec GmbH, Endothelial Function Biomarker bio-ADM to Support Risk Stratification and Clinical Management of COVID-19 Patients
E-Mail
Aachen, Germany and Hennigsdorf/Berlin, Germany, May 4, 2021 - German University Hospital Uniklinik RWTH Aachen ( Uniklinik RWTH Aachen ) and diagnostics company SphingoTec GmbH ( SphingoTec ) today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and management of patients suffering from severe COVID-19, in need for escalated intensive care treatment (1). A team lead by the clinical researchers at Uniklinik RWTH Aachen has shown that high bio-ADM levels indicate the severity of the acute respiratory distress syndrome (ARDS), the subsequent need for organ support, and poor outcomes in severely ill COVID-19 patients. Bioactive Adrenomedullin (bio-ADM) is a hormone regulating endothelial function and has been previously validated in over 35.000 patients with diseases where endothelial dysfunction plays a key role, such as sepsis, septic shock, cardiogenic shock, and acute heart failure.